drugset / Trial / NCT04276662
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, parallel design, single-dose pharmacokinetic (PK) study to assess the safety, tolerability, and PK of a single dose of 50 mg of DS-3201b in participants with normal and impaired hepatic function.
Timeline
- Start
- 2019-11-21
- Primary completion
- 2021-02-23
- Completion
- 2021-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valemetostat | Small molecule | 50 mg | — |
Indications
No indication recorded.